Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Supratentorial Glioblastoma: early-phase trial registry
1 of 3 indexed Supratentorial Glioblastoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Supratentorial Glioblastoma: 3 US clinical trials tracked, 1 recruiting.
Supratentorial Glioblastoma is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Istari Oncology, running 1 of these trials.
Enrollment posture brief
Registry condition supratentorial-glioblastoma
OPEN 1 | RECR 33% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Supratentorial Glioblastoma lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Supratentorial Glioblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Supratentorial Glioblastoma is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
Leland Metheny
NCT05052957
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
Mayo Clinic
NCT03197506
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
Istari Oncology
NCT04479241
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Supratentorial Glioblastoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Supratentorial Glioblastoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Supratentorial Glioblastoma page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Supratentorial Glioblastoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Istari Oncology sponsors the most Supratentorial Glioblastoma trials on record, review their full trial history before evaluating a specific study. See Istari Oncology's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Supratentorial Glioblastoma condition card totals 3 registered trials; most-linked intervention lerapolturev; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.